NFE2L2 and non-small cell lung carcinoma: Given the critical role of TIME in empowering NRF2-addicted NSCLC, new compounds or repurposed drugs that treat lung tumors with aberrant KEAP1-NRF2 signaling pathway should be tested in an intact immune system.